The Interleukin 23 Receptor pipeline drugs market research report outlays comprehensive information on the Interleukin 23 Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Interleukin 23 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Immunology, Gastrointestinal, Infectious Disease, and Musculoskeletal Disorders which include the indications Psoriasis, Plaque Psoriasis (Psoriasis Vulgaris), Crohn’s Disease (Regional Enteritis), Colitis, Coronavirus Disease 2019 (COVID-19), and Psoriatic Arthritis. It also reviews key players involved in Interleukin 23 Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Interleukin 23 Receptor pipeline targets constitutes close to seven molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical, and Discovery stages are 1, 4, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Interleukin 23 Receptor overview
Interleukin 23 Receptor is a type I cytokine receptor that in humans is encoded by a gene IL23R. It pairs with the receptor molecule IL12RB1/IL12Rbeta1, and both are required for IL23A signaling. IL23 binds and mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis.
For a complete picture of Interleukin 23 Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
